// App-Quantinova.ai

1895 : Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Farhad Ravandi

  • Nicholas J. Short

  • Partow Kebriaei

  • Xuelin Huang

  • Nitin Jain

  • Marina Konopleva

  • Guillermo Garcia-Manero

  • Richard E. Champlin

  • Tapan M. Kadia

  • Koichi Takahashi

  • Naval Daver

  • Hind Rafei

  • Joseph D. Khoury

  • Jeffrey L. Jorgensen

  • Sa A Wang

  • Maria R Khouri

  • Jovitta Jacob

  • Rebecca Garris

  • Susan M. O'Brien

  • Elias Jabbour

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of California Irvine Health Chao Family Comprehensive Cancer Center, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Hematocrit

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Blinatumomab

  • Methotrexate

  • Vincristine

  • Cytarabine liposomal

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved